Vernal Biosciences, a leading contract development and manufacturing organization (CDMO) for mRNA therapies, sought to accelerate its customers’ discovery timelines.

Traditional plasmid-based DNA templates were a bottleneck, taking up to a month to prepare. To address this, Vernal evaluated Elegen’s ENFINIA™ IVT Ready DNA, a cell-free, linear template, as a faster alternative.

This study directly compares mRNA from ENFINIA IVT Ready DNA against mRNA from Vernal’s standard linearized plasmid DNA.  Key quality attributes such as yield, integrity, capping efficiency, and poly(A) tail length were assessed.

Download the case study to learn how Vernal successfully validated ENFINIA DNA as a rapid, high-performance alternative that can significantly accelerate mRNA production workflows.